What is Brookline Cap M’s Forecast for CRDL FY2025 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at Brookline Cap M issued their FY2025 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a research report issued to clients and investors on Tuesday, February 3rd. Brookline Cap M analyst F. Ahmed forecasts that the company will post earnings of ($0.30) per share for the year. Brookline Cap M has a “Strong-Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09).

Several other equities analysts have also commented on CRDL. Brookline Capital Acquisition raised shares of Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research note on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Cardiol Therapeutics Stock Performance

CRDL opened at $0.99 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.89 and a current ratio of 3.89. Cardiol Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.59. The firm has a market cap of $111.10 million, a P/E ratio of -3.32 and a beta of 1.04. The business’s fifty day moving average is $1.00 and its 200-day moving average is $1.08.

Hedge Funds Weigh In On Cardiol Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRDL. Bank of America Corp DE lifted its holdings in shares of Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after purchasing an additional 15,255 shares in the last quarter. Thompson Davis & CO. Inc. bought a new position in shares of Cardiol Therapeutics in the second quarter valued at $39,000. Boyer Financial Services Inc. acquired a new position in shares of Cardiol Therapeutics during the fourth quarter valued at about $33,000. Tejara Capital Ltd increased its position in shares of Cardiol Therapeutics by 2.2% during the second quarter. Tejara Capital Ltd now owns 3,265,819 shares of the company’s stock worth $4,442,000 after acquiring an additional 70,829 shares in the last quarter. Finally, Susquehanna International Group LLP raised its holdings in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the last quarter. 12.49% of the stock is currently owned by institutional investors and hedge funds.

More Cardiol Therapeutics News

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CRDL to a “Strong‑Buy,” highlighting bullish analyst sentiment that can spur buying interest from investors and funds. Zacks Upgrade
• Positive Sentiment: Brookline published detailed EPS estimates for 2025–2026 (quarterly losses around $0.07–$0.08; FY2026 forecast ≈ ($0.29)), which are modestly less negative than the consensus FY2026 estimate of ($0.33). The slightly improved outlook vs. consensus can be read as a relative improvement in near‑term expectations. Brookline Estimates
• Neutral Sentiment: Published short‑interest data claims a “large increase” but simultaneously reports 0 shares short and NaN changes, with a days‑to‑cover of 0.0 — the figures look inconsistent and are unlikely to be a meaningful market driver until clarified by reliable data.
• Negative Sentiment: Brookline’s forecasts still show recurring quarterly losses and a negative FY outlook (company remains unprofitable). Ongoing losses limit valuation upside and mean the stock remains sensitive to funding, clinical, or regulatory news. Brookline Estimates

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.